StockUS listing USRVXCFPINKHealthcareCapital Destroyer

Resverlogix Corp.(RVXCF) Stock Analysis | Healthcare

USD --+0.00%
Reward31Low
Risk73High
75%Data
USD —+0.00 (+0.00%) Previous close · PINK
Market cap 25.86M
Reward Ratingⓘ31 Low reward assessment · 75% data coverage
Bottom 1% of stocksView factors
Risk Ratingⓘ73 High risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on RVXCF to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Resverlogix Corp.?

, a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses.

AI Brief Pro

The brief on Resverlogix Corp.

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Resverlogix Corp.?

, a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. The company's lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein cholesterol, recent acute coronary syndrome, and post COVID-19 conditions. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 25.86M.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Moderate volatility with meaningful macro and earnings sensitivity.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Low (31)

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryBiotechnology
Beta1.072
Insider Activity
12M windowNo data
No insider activity data available for this ticker.